04/03/2018 14:45:00

Asthma and Allergy Foundation of America Study Shows A Higher Burden of Disease for Patients with Adult- and Late Childhood-onset Atopic Dermatitis vs Patients with Early Childhood-onset Atopic Dermatitis

Washington, D.C., March 04, 2018 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today announced data demonstrating a higher burden of disease for patients with adult- and late childhood-onset atopic dermatitis (AD) vs patients with early childhood-onset AD. These results are from the Atopic Dermatitis in America Study, an independent research project of the Asthma and Allergy Foundation of America in partnership with the National Eczema Association (NEA) and sponsored by Sanofi Genzyme and Regeneron.

Results of the study, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress, found: 

  • Adults with late childhood-onset AD (COAD) showed a greater adverse impact on quality of life than that of those with early COAD.
  • People with adult-onset AD showed more symptoms of depression than adults with early COAD.
  • There was no difference in disease severity among those with early-, late- COAD and adult-onset AD.

Peck Ong, MD, Associate Professor of Clinical Pediatrics at Keck School of Medicine, University of Southern California and Attending Physician at Children’s Hospital of Los Angeles is one of the lead authors of this study. He said: “The Atopic Dermatitis in America study shows that adults with late childhood-onset AD and adult-onset AD carry just as much, if not a higher, disease burden as compared to those with early childhood-onset AD.   These data help us better understand how the natural history of AD affects a patient’s disease burden and has implications as to how we allocate limited resources for diagnosis and management of different subgroups of AD patients.”

About the Atopic Dermatitis in America Study – Poster no. 412

This study was conducted for the Asthma and Allergy Foundation of America in collaboration with the National Eczema Association under the guidance of a Scientific Advisory Panel chaired by Zelma C. Chiesa Fuxench, MD, MSCE and Peck Ong, MD. The Advisory Panel includes: Mark Boguniewicz, MD; Luz Fonacier, MD; Joel Gelfand, MD, MSCE; David Margolis, MD, PhD; Lawrence Schwartz, MD, PhD; and Jonathan Silverberg, MD, PhD, MPH. Additional counsel was provided by Mitchell Grayson, MD, Eric Simpson, MD, MCR, Lynda Mitchell, MA from the Asthma and Allergy Foundation of America and Julie Block, BA, from the National Eczema Foundation.

Atopic dermatitis (AD), a chronic condition that causes skin to become dry and itchy. AD is the most common type of eczema. More than 18 million American are living with AD, which often appears as a red, itchy rash normally on the cheeks, arms and legs.

A

bout the Asthma and Allergy Foundation of America

Founded in 1953 and celebrating 65 years of service, AAFA is the oldest and largest non-profit patient organization dedicated to improving the quality of life for people with asthma, allergies and related conditions through research, education, advocacy and support. AAFA provides practical information and community-based services through its digital communities and national network of local chapters and educational support groups. Through its Kids With Food Allergies division, AAFA offers the most extensive online support community for families raising children with food allergies. AAFA also helps consumers identify products suitable for those with asthma and allergies through the asthma & allergy friendly® Certification Program. For more information, visit aafa.org.

About the National Eczema Foundation

The National Eczema Association (NEA) is a non-profit 501(c) (3) organization whose mission is to improve the health and quality of life for individuals with eczema through research, support, and education. NEA was founded in 1988 by a group of patients, medical professionals, and parents who decided they could do something more to make living with this skin disease a great deal easier. As the sole patient advocacy organization serving people with eczema, NEA is active year-round to promote eczema awareness and address issues critical to patient care.

Attachments:

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/48d4ee4b-54ba-42e8-b4d8-99e81d9125de

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f31b2e5-9e28-4cd8-b8dc-fe038f55ef0f

Sanaz Eftekhari

Asthma and Allergy Foundation of America

2029741225

sanaz@aafa.org

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Sep
 
Jeg har været med som skribent her på EI siden 2012 og jeg har haft mange gode øjeblikke ved at være..
51
16 Sep
OMXC25
Putin kan lukke samtlige banker i Europa blot ved at sende nogle penge igennem dem, og bagefter lækk..
29
18 Sep
BIOPOR
BioPorto - InvestorDagen 18.september 2018 Jeg deltog til præsentationen af BioPorto ved CFO Ole ..
24
18 Sep
PNDORA
.....lyder ikke for klogt. Nu har vi været under pres fra shortere i lang tid i Pandora som fik bank..
20
15 Sep
DANSKE
...og jeg kan supplere, man skal ikke tro på mennesker der er maniske eller totalt besatte af en giv..
16
16 Sep
BAVA
Bava var sat op til en næsten perfekt IHS, der ville sende den op i ca. 225.   Men så kommer der lig..
14
13 Sep
OMXC25
Jeg var i London i de år. Jeg kom forbi Lehman Brothers hver morgen og aften ude i Cannary Wharf. De..
14
15 Sep
BAVA
Hvilken af de to links forklarer, at Bavarian faldt 6%? Er det fordi de fik et nyt patent, eller er ..
13
17 Sep
BAVA
dette er en delvis gentagelse af mit indlæg fra weekenden Min tilgang til den er at jeg ikke forstå..
12
15 Sep
DANSKE
Det du skriver er da voldsomt selvmodsigende. Muligt 6212 får ret, men indtil videre er de ikke ankl..
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Squirrel AI unveiled at TechCrunch Disrupt, attracting overseas ventures to propose partnership
2
Service organization Alpha Kappa Alpha Sorority surpasses $1 million in historic one day campaign to help nation's HBCUs
3
WISeKey and OISTE.ORG to Launch at the Zermatt Summit the Anti-Illicit Trade Declaration, calling on the International Community to Address all Forms of Illicit Trade
4
Nasdaq Halts Luokung Technology Corp.
5
Senior Congressional Healthcare Policy Advisor Charlene MacDonald Joins FTI Consulting

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 September 2018 02:36:23
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB6 - 2018-09-20 03:36:23 - 2018-09-20 02:36:23 - 1000 - Website: OKAY